Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital

References

• Barbui T, Thiele J, Gisslinger H., et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. doi:10.1038/s41408-018-0054-y
   PubMed Web of Science ®Google Scholar
• Spivak JL, Longo DL. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168–2181. doi:10.1056/NEJMra1406186
   PubMed Web of Science ®Google Scholar
• Yassin MA, Taher A, Mathews V, et al. MERGE: a multinational, multicenter observational registry for myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Med. 2020;9(13):4512–4526. doi:10.1002/cam4.3004
   PubMed Web of Science ®Google Scholar
• Byun JM, Kim YJ, Youk T, Yang JJ, Yoo J, Park TS. Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013. Ann Hematol. 2017;96(3):373–381. doi:10.1007/s00277-016-2902-9
   PubMed Web of Science ®Google Scholar
• McMullin MF, James G, Duncombe AS, et al. Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study. Exp Hematol Oncol. 2015;5:14. doi:10.1186/s40164-016-0043-4
   PubMedGoogle Scholar
• Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013;27(10):1953–1958. doi:10.1038/leu.2013.74
   PubMed Web of Science ®Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167. doi:10.1186/s12885-016-2208-2
   PubMed Web of Science ®Google Scholar
• Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015;90(10):864–870. doi:10.1002/ajh.24098
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Kristinsson SY, Andersson TM-L, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30(24):2995–3001. doi:10.1200/JCO.2012.42.1925
   PubMed Web of Science ®Google Scholar
• Maynadié M, Girodon F, Manivet-Janoray I, et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d’Or (Burgundy, France). Haematologica. 2011;96(1):55–61. doi:10.3324/haematol.2010.026252
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176–2184. doi:10.1182/blood-2013-03-460154
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40(3):348–358. doi:10.1055/s-0034-1370794
   PubMed Web of Science ®Google Scholar
• Björkholm M, Hultcrantz M, Derolf ÅR. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? Best Pract Res Clin Haematol. 2014;27(2):141–153. doi:10.1016/j.beha.2014.07.003
   PubMed Web of Science ®Google Scholar
• Yogarajah M, Tefferi A. Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin proc. 2017;92(7):1118–1128. doi:10.1016/j.mayocp.2017.05.010
   PubMed Web of Science ®Google Scholar
• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–1881. doi:10.1038/leu.2013.163
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–5133. doi:10.1182/blood-2012-07-444067
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895–2901. doi:10.1182/blood-2008-07-170449
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–1708. doi:10.1182/blood-2009-09-245837
   PubMed Web of Science ®Google Scholar
• Valladares X, Rojas C, Peña C, et al. Characterization of Philadelphia-negative myeloproliferative neoplasms in the Chilean public health system: multicentric study. Blood. 2018;132(Supplement 1):5479. doi:10.1182/blood-2018-99-117610
   Web of Science ®Google Scholar
• Barzilai M, Kirgner I, Avivi I, et al. Characteristics and outcomes of young adults with Philadelphia‐negative myeloproliferative neoplasms. Eur J Haematol;2019. ejh.13232. doi:10.1111/ejh.13232
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–397. doi:10.1200/JCO.2010.32.2446
   PubMed Web of Science ®Google Scholar
• Porto-Soares MA, de Oliveira RD, Cortopassi GM, Machado-Neto JA, Palma LC, de Figueiredo-Pontes LL. Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms. Hematol Transfus Cell Ther. 2020;42(3):238–244. doi:10.1016/j.htct.2019.07.008
   PubMedGoogle Scholar
• Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, et al. Clinical manifestations and risk Factors for complications of Philadelphia chromosome-negative myeloproliferative neoplasms. Asian Pac J Cancer Prev. 2015;16(12):5013–5018. doi:10.7314/APJCP.2015.16.12.5013
   PubMedGoogle Scholar
• Bose P. Myelofibrosis with cytopenias. Clin Lymphoma Myeloma Leuk. 2017;17:S30–S31. doi:10.1016/j.clml.2017.08.018
   Google Scholar
• Tefferi A. Anemia in myelofibrosis—prevalence, the U2AF1 connection, new treatments. Blood Cancer J. 2017;7(12):648. doi:10.1038/s41408-017-0032-9
   PubMed Web of Science ®Google Scholar
• Nangalia J, Grinfeld J, Green AR. Pathogenesis of myeloproliferative disorders. Annu Rev Pathol Mech Dis. 2016;11(1):101–126. doi:10.1146/annurev-pathol-012615-044454
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–397. doi:10.1016/j.ccr.2005.03.023
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couédic J-P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148. doi:10.1038/nature03546
   PubMed Web of Science ®Google Scholar
• Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123(22):e123–33. doi:10.1182/blood-2014-02-554634
   PubMed Web of Science ®Google Scholar
• Skorczewski T, Erickson LC, Fogelson AL. Platelet motion near a vessel wall or thrombus surface in two-dimensional whole blood simulations. Biophys J. 2013;104(8):1764–1772. doi:10.1016/j.bpj.2013.01.061
   PubMed Web of Science ®Google Scholar
• Walton BL, Lehmann M, Skorczewski T, et al. Elevated hematocrit enhances platelet accumulation following vascular injury. Blood. 2017;129(18):2537–2546. doi:10.1182/blood-2016-10-746479
   PubMed Web of Science ®Google Scholar
• Yap YY, Law KB, Sathar J, et al. The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia. Exp Hematol Oncol. 2018;7(1):31. doi:10.1186/s40164-018-0124-7
   PubMed Web of Science ®Google Scholar
• Vannucchi A, Guglielmelli P. JAK2 mutation-related disease and thrombosis. Semin Thromb Hemost. 2013;39(05):496–506. doi:10.1055/s-0033-1343890
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management. Am J Hematol. 2020;95(12):1599–1613. doi:10.1002/ajh.26008
   PubMed Web of Science ®Google Scholar
• Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857–5859. doi:10.1182/blood-2011-02-339002
   PubMed Web of Science ®Google Scholar
• Sevindik OG, Mersin S, Katgi A, et al. IPSET-thrombosis better identifies thrombosis-free survival: a Turkish cohort. Clin Lymphoma Myeloma Leuk. 2015;15(6):e101–e104. doi:10.1016/j.clml.2015.02.004
   PubMedGoogle Scholar
• Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1(1):97. doi:10.1001/jamaoncol.2015.89
   PubMed Web of Science ®Google Scholar
• Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM. Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review. Ann Intern Med. 2017;167(3):170. doi:10.7326/M17-0284
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016;101(8):926–931. doi:10.3324/haematol.2016.146654
   PubMed Web of Science ®Google Scholar